The consensus price target for Cullinan Therapeutics, Inc. (NASDAQ: CGEM) has slightly decreased over the past year but remains stable in recent months.Morgan Stanley analysts have set a price target of $19 for CGEM, indicating a positive outlook for the stock.Cullinan's focus on developing therapies for cancer and immune-related diseases positions it well in the competitive biopharmaceutical industry.Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is a clinical-stage biopharmaceutical company that focuses on de ...

Emergent BioSolutions (NYSE:EBS) Q4 2025 Earnings call February 26, 2026 05:00 PM ET Company ParticipantsFrank Vargo - TreasurerJoe Papa - President and CEORich Lindahl - EVP and CFOOperatorPlease be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Frank Vargo, Treasurer. Please go ahead.Frank VargoGood afternoon, everyone. Thank you for joining today as Emergent discusses their operational and financial results for the fourth quart ...

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that its subsidiaries, Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited, have filed a patent infringement lawsuit under the Hatch-Waxman Act related to Recorlev® (levoketoconazole) in the United States District Court for the District of New Jer. ...

Pacira BioSciences (NasdaqGS:PCRX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker1Good day, and thank you for standing by. Welcome to the Q4 2025 Pacira BioSciences Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To with ...

Core Viewpoint - Mirum Pharmaceuticals is focused on developing therapies for rare liver diseases, with significant revenue growth driven by innovative treatments like Livmarli and bile acid drugs [1][6]. Financial Performance - Mirum reported a 50% increase in revenues for the fourth quarter, driven by strong sales of Livmarli and bile acid drugs, despite incurring a net loss [3][6]. - The company has a market capitalization of approximately $4.77 billion, indicating its size and market presence [5][6]. Stock Performance - Currently, MIRM's stock is priced at $92.22, reflecting a 15.10% decrease, with fluctuations between $90.26 and $100.19 on the trading day [4][6]. - Over the past year, the stock reached a high of $107.41 and a low of $36.88, indicating significant volatility [4]. Analyst Outlook - RBC Capital set a price target of $128 for MIRM, suggesting a potential upside of about 36% from its trading price of $94.14 at the time [2].

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties an ...

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties an ...

Core Viewpoint - BGM Group Ltd. has received a notification from Nasdaq regarding non-compliance with listing rules due to the late filing of its Annual Report on Form 20-F for the fiscal year ended September 30, 2025 [1][2]. Compliance and Regulatory Actions - The company has 60 calendar days to submit a plan to Nasdaq to regain compliance, with a potential extension of up to 180 days if the plan is accepted [2]. - If the plan is not accepted, the company can appeal the decision to a Hearing Panel, but the notification does not immediately affect the listing of its class A ordinary shares [3]. Company Operations and Focus - BGM Group Ltd. focuses on technology fields including AI applications, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals [5]. - In AI applications, the company utilizes advanced analytics and AI Agent technology to provide solutions for insurance companies, covering areas such as sales, underwriting, claims processing, and customer service [6]. - The biopharmaceutical division produces oxytetracycline API, crude heparin sodium, and licorice preparations, integrating AI-assisted decision-making to optimize supply chains and improve process efficiency [7].

Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new p ...

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS II study with higher doses expected in Q1 2026 Aleniglipron Phase 3 initiation expected in 2H 2026 Initial data from the ongoing Phase 1 study of oral small molecule amylin receptor agonist ACCG-2671 and Phase 1 initiation of second oral amylin compound ACCG-3535 expected in 2H 2026 Cash, cash equivalents and s ...